Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Trevena, Inc

  • Mark A. Demitrack, Trevena

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain. The Company has three novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the treatment of acute migraine, and TRV734 for pain and/or management of opioid dependence. In its preclinical programs, Trevena is evaluating a set of novel S1P receptor modulators that may offer a new, non-opioid approach to managing chronic pain.

  • Date:Tuesday, February 12
  • Time:9:15 AM - 9:30 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23556
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:To Provide Company & Product Updates
  • Company Website:www.trevena.com
  • Company HQ City:Wayne
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Ticker:TRVN
  • Exchange:Nasdaq
  • CEO/Top Company Official:Carrie Bourdow
  • Year Founded:2007
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Oliceridine
  • Development Phase of Primary Product:NDA Preparation / In Review
Speakers
Mark A. Demitrack
Trevena
Back